Form 4: Eli Lilly Executive Jacob Van Naarden Reports Stock Transactions

Eli Lilly executive Jacob Van Naarden reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.

Summary

• Jacob Van Naarden, an Executive Vice President at Eli Lilly, reported transactions involving the company's common stock and restricted stock units.
• On February 1, 2024, Van Naarden acquired 3,618 shares of common stock through the vesting of restricted stock units.
• Also on February 1, 2024, 1,685 shares were disposed of at a price of $645.61 per share.
• Following these transactions, Van Naarden directly owns 13,778 shares of common stock and indirectly owns 4,342 shares through the Van Naarden Family Trust.
• The restricted stock units were converted into 3,618 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing of stock transactions by an executive, which is neither positive nor negative in itself.

Industry Context

This is a routine filing related to executive stock transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Executive stock transactions are a standard practice in publicly listed companies like Eli Lilly.
• Similar filings are regularly made by executives at comparable pharmaceutical companies such as Pfizer (PFE) and Merck (MRK).
• The reporting requirements are consistent across all companies listed on the US stock exchanges.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine executive stock transactions.

Key Dates

Keywords

insider trading, stock transaction, restricted stock units, common stock, executive, Eli Lilly, LLY